Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide, are widely recognized for their efficacy in treating metabolic disorders, including type 2 diabetes (T2D) and obesity (1). Here, GLP1R is linked to metabolic disease.